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Abstract
Aims: Implantable defibrillators are considered life-saving therapy in heart failure (CHF) patients.
Surprisingly, the recent Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) reached an
opposing conclusion from that of numerous other trials about their survival benefit in patients with
advanced CHF. A critical analysis of common control trial design may explain this paradoxical
finding, with important implications for future studies.
Methods and Results: Common control trials compare several intervention groups to a single
rather than separate control groups. Though potentially requiring fewer patients than trials using
separate controls, variation in the common control group will influence all comparisons and creates
correlations between findings. During subgroup analyses, this dependency of outcomes may
increase belief in the presence of a real subgroup effect when, in fact, it should increase skepticism.
For example, a high (r = 0.92), statistically unlikely (p = 0.052) correlation between comparisons
was observed across the subgroups reported in SCD-HeFT. Such concordance between
amiodarone and a defibrillator across subgroups was unexpected, given how much the effects of
these treatments significantly differed from one another in the main study. This suggests the study's
subgroup findings (specifically the absence of benefit from defibrillators in advanced CHF) were not
necessarily a consequence of treatment; more likely, they resulted from variation in what the
treatments were compared against, the common control.
Conclusion:  Common control trials can be more efficient than other designs, but induce
dependence between treatment comparisons and require cautious interpretation.
Background
Implantation of a cardioverter defibrillator is considered
life-saving therapy in patients with moderate to severe
symptoms of congestive heart failure (CHF) and dimin-
ished ventricular function. In most defibrillator trials,
patients with "sicker" hearts derived the largest survival
benefit from such treatment [1-4]. Surprisingly, a recent
randomized trial, Sudden Cardiac Death in Heart Failure
(SCD-HeFT), reached an opposing conclusion [5]. The so-
called "SCD-HeFT paradox" was the puzzling finding that
survival in the subgroup of patients with New York Heart
Association (NYHA) Class III CHF was not improved by
receipt of an implantable defibrillator. This apparent con-
tradiction may not, however, represent a true clinical phe-
nomenon, but rather a consequence of trial design.
SCD-HeFT was somewhat unusual among defibrillator
trials in having used a common control design. Our pur-
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pose here is to describe the statistical principles that are
foundational to trials using a common control and how
such a design may provide insight into apparent paradox-
ical outcomes in subgroup analyses. The rising popularity
of such trials requires that clinicians have a working
knowledge of these principles. For statistically oriented
readers, an appendix (see additional file 1) provides some
derivations and formulae.
Methods
Common control versus parallel trial designs
Figures 1 and 2 depict two studies that are identical in
evaluating the same interventions, patient population,
and having the same comparisons of interest. The separate
control design (Figure 1) consists of two trials operating in
parallel, one comparing, in this instance, amiodarone to
its own placebo control, and the other comparing an
implantable defibrillator to its own separate (sham) con-
trol. In contrast, the common control design (Figure 2)
compares the same active treatments, amiodarone and a
defibrillator, against a single common control group,
which is administered an oral placebo. A prominent fea-
ture of this design, not encountered by the parallel two-
group design, is the simple fact that variation in the con-
trol group affects all comparisons against it and hence
induces correlations between findings. Indeed the pair-
wise correlation between comparison measures is ρ = 1/
(1+k) if the common control group has k times as many
patients as each comparison group (for example, the
expected correlation ρ = 0.5 if the common control is the
same size as each treatment group, that is, if k = 1).
Allocation of patients to treatment and control groups
How patients are distributed (allocated) to intervention
groups in common and separate control studies is based
on a number of considerations. These include attempting
to minimize costs from the various treatments to which
they might be assigned, and maximizing statistical power.
Depiction of a trial designed with 2 separate controls Figure 1
Depiction of a trial designed with 2 separate controls. The corresponding study-wide alpha (α) and beta (β) calculations are 
depicted below the design. The designated relative samples sizes are those for maximum efficiency. In the separate control trial 
design shown, two trials operate side-by-side, one comparing amiodarone to its own placebo control and the other comparing 
a defibrillator to its own (sham) control. The most efficient allocation of patients in this instance is 1:1.
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From the latter perspective, for a simple two-group com-
parison, where each intervention is compared against its
own control, a 1:1 allocation of patients affords the great-
est efficiency, that is, it minimizes the number of patients
required for study. This is not the case for comparisons
involving a common control. Specifically, if a fixed
number of patients are allocated in a ratio of 1:1:...:1:k to
a variety of m interventions (A1, A2,... Am), and a common
control group, the efficiency is maximized when
[6]. Thus in the instance where two treatment
groups are compared to a common control (the scenario
we consider in the remainder of this paper), the most effi-
cient allocation of patients will be when the ratio of
km =
Depiction of a trial using a common control design testing the same clinical question as one with 2 separate controls (shown in  figure 1) Figure 2
Depiction of a trial using a common control design testing the same clinical question as one with 2 separate controls (shown in 
figure 1). The corresponding study-wide alpha (α) and beta (β) calculations are depicted below the design. The designated rel-
ative samples sizes are those for maximum efficiency. In the common control design shown, the active treatments of amiodar-
one and a defibrillator are compared against a common control, which is administered an oral placebo. The most efficient 
allocation of patients to these treatments and the common control is in the ratio of 1:1:√2.
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patients assigned to the control group is  , resulting in
an allocation ratio of 1:1:1.4.
Defining and assigning study-wide error
In comparing common and separate control designs, one
must distinguish study-wide error from the error assigned
to individual comparisons. For either design, the study-
wide alpha (α) is defined as the likelihood of seeing a
benefit from either of the treatments (amiodarone or a
defibrillator, for example), when no such benefit actually
exists. Conversely, the study-wide beta (β) is defined as
the likelihood of missing all benefits from the treatment
interventions when both actually have benefit.
For a separate control trial design (Figure 1), one typically
begins by assigning errors α1 and α2 for each comparison
before calculating study-wide error. The study-wide α is
then given by α = 1 - (1 - α1)(1 - α2). The study-wide β is
given by β = β1·β2, where β1 and β2 are the betas assigned
for each comparison [7]. If, for example, an α of 0.05 and
a β of 0.1 were assigned to each comparison depicted in
Figure 1, the study-wide α is 1 - (1 - .09)2 or 0.0975 and
the study-wide β is 0.1·0.1 or 0.01.
Conversely, in the common control design (Figure 2), one
typically begins by assigning study-wide error (in this
example α = 0.05 and β = 0.1) before calculating the val-
ues to be assigned for each individual comparison. In this
instance, assuming that α and β are split evenly between
two individual comparisons, then α1= α2 = approximately
0.0263 (from the formula derived in the Appendix (see
additional file 1, section A)), and β1 = β2 = approximately
0.238 (see the formula derived in the Appendix (see addi-
tional file 1, section B)). Thus, even though designed to
address the identical question, the typical manner of
assigning error results in vastly different study-wide α and
β for the common and separate control designs.
Optimizing study efficiency
Figure 3 depicts the ratio of sample sizes required for a
hypothetical intervention using common to separate con-
trol designs with all other design parameters being the
2
Efficiency of comparing two interventions, splitting the study wide alpha and beta equally, using the common control design  compared to the optimal parallel group design (1:1 allocation) as a function of the allocation ratio 1:1:k across a wide spectrum  of Type I (alpha) and Type II (beta) errors Figure 3
Efficiency of comparing two interventions, splitting the study wide alpha and beta equally, using the common control design 
compared to the optimal parallel group design (1:1 allocation) as a function of the allocation ratio 1:1:k across a wide spectrum 
of Type I (alpha) and Type II (beta) errors.Trials 2008, 9:24 http://www.trialsjournal.com/content/9/1/24
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same and with α1 = α2 and β1 = β2. When the proportion
of subjects allocated to the common control group (k) is
0.75 < k < 2.5, the common control design is more effi-
cient (resulting in approximately a 15% reduction in sam-
ple size for √2 ≤ k < 2); whereas the common control
design is less efficient than the separate control design
when k < 0.67 or k > 4.
Subgroup analyses in a common control study
Variation in the common control will affect all compari-
sons made against it. This can lead to observing similar
effects from differing treatments in a subgroup of patients,
which may instill greater confidence in the presence of a
subgroup effect, when, in fact, there should be less. The
risk of variation in a group is proportional to the recipro-
cal of the square root of the group size. Thus the relative
impact of the common control group on spurious sub-
group findings increases as the allocation ratio decreases
(for example, 1:1:1 rather than 1:1: ). Notably, the
presence of a common control may actually help deter-
mine whether a subgroup finding is related to the treat-
ment under study, since, if due to the control group, all
comparisons should be impacted, whereas if due to an
intervention, only the comparison of that intervention
against the control should be impacted.
Calculating correlations
The magnitude of the expected correlation of compari-
sons between subgroups and a common control can be
calculated. Presuming that outcomes in each subgroup are
similar to the overall outcomes of the study, the expected
correlation between the pairs of log relative risks for the
comparisons of each intervention to the common control
among subgroups is derived in the Appendix (see addi-
tional file 1, section C). The expected correlation is related
to the reciprocal of the allocation ratio and (in the case
where this is 1:1:1) is approximately equal to
 where OR represents the odds ratio
for the overall effect of each treatment versus the common
control.
Results
In SCD-HeFT, patients with NYHA Class II or III CHF, an
ejection fraction ≤ 35%, and receiving standard heart fail-
ure therapies were randomly assigned to oral amiodarone,
a defibrillator, or oral placebo (common control group)
in a 1:1:1 ratio [5]. SCD-HeFT was powered at 90% to
detect a 25% reduction in mortality at an alpha level of
0.025. The salient findings of the trial were that a defibril-
lator reduced total mortality by 23%, whereas amiodar-
one had no significant effect upon survival (Figure 4).
Among the prespecified subgroup defined by CHF class,
treatment with a defibrillator resulted in an appreciable
reduction in mortality among patients with NYHA Class II
CHF The respective hazard ratios for defibrillator therapy
versus placebo (common control) and for amiodarone
versus placebo (common control) were 0.54 (p = 0.001)
and 0.85 (p = 0.17). Unexpectedly, no benefit of the defi-
brillator was apparent in those with NYHA Class III CHF,
but that cohort was apparently harmed by amiodarone
therapy. In class III CHF patients, the corresponding haz-
ard ratios were 1.16 (p = 0.30) and 1.44 (p = 0.01). The
reported p values for the tests of interaction between defi-
brillator therapy and NYHA class and between amiodar-
one therapy and NYHA class were 0.001 and 0.004,
respectively.
Clinical interpretation
That patients with NYHA CHF Class III in SCD-HeFT had
no mortality benefit attributable to a defibrillator has
been taken by some to suggest that prophylactic implan-
tation of a defibrillator is not helpful for improving sur-
vival among patients in more advanced stages of CHF.
Compared to patients with better ventricular function, it
is argued that the prospect of death from worsening circu-
latory (pump) failure is proportionately higher in those
with poor function and not something one would neces-
sarily expect to be altered by a device that only affords
treatment directed against arrhythmias [8]. This contrasts
with results from other studies that indicated that a defi-
brillator improved outcome in patients with more
advanced heart failure [1-4,9].
2
1
OR1 1O R 2 1 + () + ()
Primary outcome in Sudden Cardiac Death in Heart Failure  Trial (SCD-HeFT) Figure 4
Primary outcome in Sudden Cardiac Death in Heart Failure 
Trial (SCD-HeFT). Kaplan-Meier estimates of death from any 
cause, comparing amiodarone and defibrillator therapy 
against their common control (placebo) group. (Copyright 
2005, Massachusetts Medical Society [5]. All rights 
reserved.).Trials 2008, 9:24 http://www.trialsjournal.com/content/9/1/24
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Statistical insights
Although there are plausible clinical reasons for the differ-
ent outcome in SCD-HeFT, its use of a common control
design permits investigation of the possibility that the
explanation lies in variation in the common control.
Because of the relatively small proportion of patients allo-
cated to the control limb, the trial was subject to a rela-
tively large impact from the common control in subgroup
analyses. Based on the 5 year mortality rate estimates pro-
vided in SCD-HeFT, the odds ratios for the effect of treat-
ment with a defibrillator or amiodarone versus the
common control were 0.719 and 0.912, respectively. This
results in an expected correlation of the log of the relative
risks for the comparisons (intervention versus common
control) in the 7 subgroups from SCD-HeFT shown in Fig-
ure 4A without an a priori expectation of an interaction
(that is, excluding the beta-blocker subgroup for whom an
interaction with amiodarone might be expected) of
 (see formula in the Calculating
Correlations section above). However, the observed corre-
lation was 0.92. Assuming independence of the sub-
groups (an assumption supported by other studies having
a similar population, such as the Dual Chamber and VVI
Implantable Defibrillator (DAVID) trial, in which pair-
wise correlations between subgroups ranged from 0 to
0.13) [10], the probability of observing this magnitude of
correlation (r = 0.92) in subgroup findings when the
expected value should be 0.55 is p = 0.052 (see Appendix
(additional file 1, section D)) [11].
This unexpected uniformity for subgroup responses
between patients treated with amiodarone and those
treated with a defibrillator is illustrated in Figures 5 and 6.
Figure 5 shows the reported hazard ratios for subgroups of
patients treated with amiodarone or a defibrillator as
compared with placebo in SCD-HeFT. These were used to
generate Figure 6. In depicting the superimposed hazard
ratios shown in Figure 6, the absolute hazard ratio at the
bottom of Figure 5 was ignored, and the hazard ratios
were exactly aligned for the topmost subgroup defined by
each variable (see insert in figure 6). For example, for the
female and male subgroups that were defined by the sex
variable, we exactly aligned the hazard ratios for the effect
of treatment with amiodarone and treatment with a defi-
brillator in females. When the hazard ratios are "standard-
ized" in this manner for one subgroup (e.g. females), the
hazard ratios for the complementary subgroup(s) (e.g.
males) indicate the quality and quantity of interaction
between the treatments and the subgroups defined by that
variable on outcome. This process was applied to each of
the subgroups defined by the variables shown in Figure 5,
excepting use of beta blockers (which might be expected
to interact with treatment), and the NYHA subgroups
were added at the bottom of the figure. The hazard ratios
for the effect of treatment with amiodarone and treatment
with a defibrillator on outcome are readily seen to be
qualitatively, if not quantitatively, similar in virtually all
subgroups. To find such a strong similarity in subgroup
effects from two interventions whose effects proved to be
far different in the main trial is surprising, and suggests
that many of the subgroup findings resulted from what
each of the treatments was compared against, that is, the
common control.
SCD-HeFT paradox
Among its individual subgroup comparisons, SCD-HeFT
reported a significant benefit for defibrillator therapy in
Class II CHF patients, a significant harm for amiodarone
therapy in Class III CHF patients, and associated signifi-
cant tests of interaction between each treatment and the
NYHA class. However, the quantitatively similar effects
seen among the NYHA subgroups in the bottom of figure
6 suggest that these interactions were likely the result of a
common control phenomenon, not treatment. Indeed, if
one eliminates the common control, the relative hazards
for amiodarone versus defibrillator therapy (1.57 and
1.24 for Class II and Class III CHF respectively) were not
significantly different (p~0.22). Thus the significant inter-
actions reported by SCD-HeFT appear to depend upon the
common control, and suggests that the failure to observe
a benefit from an implanted defibrillator in patients with
NYHA Class III heart failure was not a consequence of
treatment, but more likely was caused by a variation in the
common control group.
1 1 719 1 912 0 55 /. . . •≈
Hazard ratios for subgroups of patients treated with amio- darone or a defibrillator as compared with placebo in the  Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Figure 5
Hazard ratios for subgroups of patients treated with amio-
darone or a defibrillator as compared with placebo in the 
Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
Abbreviations: ft = feet; ICD = implantable defibrillator; LVEF 
= left ventricular ejection fraction. (Copyright 2005, Massa-
chusetts Medical Society [5]. All rights reserved.).Trials 2008, 9:24 http://www.trialsjournal.com/content/9/1/24
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Superimposed hazard ratios for subgroups of patients treated with amiodarone or a defibrillator, compared to the common  control in SCD-HeFT Figure 6
Superimposed hazard ratios for subgroups of patients treated with amiodarone or a defibrillator, compared to the common 
control in SCD-HeFT. The figure was created by superimposing the hazard ratios with confidence intervals reported in SCD-
HeFT from the left portion of Figure 5 (depicting amiodarone versus placebo) upon those on the right (defibrillator therapy 
versus placebo) as shown in the circular inset (see text for specific construction). Dots with solid (or dashed) horizontal lines 
represent the hazard ratio and confidence intervals for the effect of treatment with a defibrillator (or amiodarone) versus the 
common control on outcome. The vertical dotted line represents the alignment of the hazard ratios for the topmost subgroup 
defined by each variable. Subgroups with discordant treatment effects are highlighted as green text. Abbreviations: ft = feet; 
LVEF = left ventricular ejection fraction. (Copyright 2005, Massachusetts Medical Society [5]. All rights reserved. Adapted with 
permission.).Trials 2008, 9:24 http://www.trialsjournal.com/content/9/1/24
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Discussion
Benefits of a common control
Trials using common rather than separate control groups
have many desirable features. Perhaps the most important
of these is conserving patients, the most valuable resource
in a trial. A common control design with the optimal pro-
portion of subjects allocated between treatment groups
and the control can significantly reduce the number of
patients required for study. From this perspective, by hav-
ing a common control design with an allocation ratio of
1:1:1, less than the optimal of 1:1:√2, SCD-HeFT missed
the opportunity to utilize its design to maximum effi-
ciency. As a result, it may have enrolled more patients
than required to test their hypotheses. It should be noted,
however, that even with less than optimal allocation, the
SCD-HeFT design was still more efficient than a parallel
group design (figure 3).
In addition to these practical considerations, failure to
take full advantage of study design efficiency also has eth-
ical ramifications. The need to enroll fewer subjects in a
trial means fewer persons being placed at risk for the inter-
ventions being tested. Because the optimal subject alloca-
tion ratio in a common control trial (1:1:√2 for a 2-
treatment study) results in a higher proportion of subjects
in the control group, this also prevents placing more
patients in harm's way than necessary, were the trial's
interventions to be proven harmful.
Peril of a common control
Another potentially advantageous, but also perilous, fea-
ture of the common control design is the dependency
such a design induces between comparisons of the active
treatments with the common control. This design pro-
vides a useful tool to help evaluate the likelihood that a
subgroup finding is actually due to a treatment effect. For
example, seeing a positive subgroup finding for one treat-
ment, but not for others, lends support to the presence of
a true effect from treatment. Conversely, a positive sub-
group finding for all the tested treatments is more likely to
result from what the comparisons have in common,
namely the control group, and hence supports their origin
from chance variation in the common control rather than
from the interventions themselves. In the latter instance,
the peril lies in the natural tendency to develop greater
confidence in such multiple positive findings as indicative
of a real subgroup phenomenon, rather than their raising
suspicion for the presence of a common control group
effect. The controversial SCD-HeFT treatment paradox
may represent a heretofore unrecognized example of this
peril; puzzling until seen as a consequence of trial design,
rather than a clinical phenomenon. This observation may
explain and allay some of the concern for why the results
for NYHA Class III CHF seen in SCD-HeFT did not agree
with other studies.
Limitations
Our analysis of SCD-HeFT was based on published
descriptions of their design and findings. We did not have
access to the patient specific data and hence could not
examine the relationships between various subgroups in
more detail. Furthermore, our statistical arguments are
intended to provide further insight and guidance in inter-
pretation, not necessarily exclude other plausible explana-
tions for the results of these trials.
Conclusion
Common control trials compare several intervention
groups to a single rather than to separate control groups.
Such trials can be more efficient than those using separate
control groups, but induce a dependence between the
comparisons of their treatments with the common con-
trol. The efficiency of a common control trial's design is
reduced and even negated if the allocation ratio between
treatment and control groups strays far from the optimal,
and its risk for fortuitous subgroup findings will be
enhanced when the allocation to the common control is
smaller than optimal. These principles may explain some
of the paradoxical and discordant findings in recent trials,
and can serve to guide the design and analyses of future
clinical trials using a common control.
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